Vertex stock jumps on FDA approval of new non-opioid painkiller
Vertex Pharmaceuticals (VRTX) stock is rising following Food and Drug Administration (FDA) approval of Journavx, a non-opioid pain medication designed to treat moderate to severe acute pain. The new drug represents a potentially significant advancement in pain management,
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
For investors seeking deeper insights, InvestingPro offers comprehensive analysis with additional metrics and expert tips that could help evaluate Vertex's financial strength. The majority of ...
Cantor Fitzgerald reiterated its Overweight rating and a $480.00 price target for Vertex Pharmaceuticals Incorporated (NASDAQ ...
The simplest way to invest in stocks is to buy exchange traded funds. But you can do a lot better than that by ...
Wells Fargo analyst Mohit Bansal downgraded Vertex Pharmaceuticals (VRTX) to Equal Weight from Overweight with an unchanged price target of ...
Zacks.com on MSN4d
Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You TradeIn the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $440.68, marking a -0.72% move from the previous day.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback